First-line treatment for advanced non-squamous lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug combination for people with a type of lung cancer that has spread or cannot be removed by surgery. It compares the new combination to the current standard treatment to see which works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a diagnosis of non-squamous non-small cell lung cancer that is locally advanced or has spread.
- You have not received any prior treatment for this cancer.
- Your cancer shows no common gene mutations (like EGFR) that have targeted therapies.
- You are in generally good health (able to do light activity) and can provide a tumor tissue sample.
- Your organs (like heart, kidneys, liver) are working well enough, and you have no recent serious health issues.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing a new drug (BL-M07D1) compared to a standard combination of pembrolizumab and chemotherapy for people with a specific type of advanced lung cancer (non-squamous NSCLC) that has a HER2 mutation and has not been treated before. The goal is to see which treatment works better.
This trial tests a new drug (JS207) that targets both PD-1 and VEGF pathways, given alone or with other treatments, for people with advanced non-small cell lung cancer that has a specific gene change and has stopped responding to targeted therapy (TKI). The goal is to see if this combination can help shrink tumors or slow cancer growth.
This study tests a new drug combination, BL-M07D1 plus pembrolizumab (an immunotherapy), for people with a certain type of advanced lung cancer that has high levels of HER2 protein. The goal is to see if the combination is safe and effective for people who have not been treated with HER2-targeting drugs before.
This trial tests a new drug called HB0025 combined with chemotherapy for people with advanced non-squamous non-small cell lung cancer who haven't had treatment before. It compares this combination to the current standard treatment (tislelizumab plus chemo) to see which works better.
This study tests a new combination treatment (BL-B01D1 plus a bispecific antibody) against a standard chemotherapy-plus-bispecific-antibody combo for people with advanced squamous non-small cell lung cancer who have not yet received any treatment. It aims to see if the new drug combo works better at shrinking tumors or delaying cancer growth.
This trial tests a new drug (SCTB41) combined with chemotherapy for people with advanced squamous non-small cell lung cancer who have not had any prior treatment. It aims to see if this combination works better than standard therapy.
Hear when a new Non-squamous Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.